Aurore Lejeune-Dodge

CSO at Topia Life Science

Presenter

With 20 Years experience in Scientific & Strategic Leadership in UK & Global Life Science, Aurore joined Topia Life Sciences as Chief Scientific Officer in January 2026. Her expertise primarily focus on Drug Discovery and the delivery of novel drugs to the Clinics for high unmet medical needs across multiple Therapeutic Areas (Oncology, I&I, CNS, CardioMetabolic, Rare Disease). Experienced drug hunter, Aurore started her Pharmacology career in Cancer Research Horizons (part of Cancer Research-UK), spanning from Oncology project leadership to lab automation technologies and HTS/Compound Management specialist. Advancing assets to PreClinical stage, such as the Autotaxin Program currently completing Phase I for PDAC indication. In 2021, Aurore joined Exscientia, TechBio leader spearheading the transformation of small molecule Drug Discovery with application of AI/ML Technologies. As Director of Alliance & Portfolio Management, she led strategic commercial partnerships with global Pharma supporting Exscientia’s expansion. Passionate about the transformative impact of TechBio over Drug Discovery , Aurore is now engineering drug pipeline strategy, small molecules Program delivery and Tech-led Operations at Topia LifeSciences (UK & India).